JP2012522007A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522007A5
JP2012522007A5 JP2012502295A JP2012502295A JP2012522007A5 JP 2012522007 A5 JP2012522007 A5 JP 2012522007A5 JP 2012502295 A JP2012502295 A JP 2012502295A JP 2012502295 A JP2012502295 A JP 2012502295A JP 2012522007 A5 JP2012522007 A5 JP 2012522007A5
Authority
JP
Japan
Prior art keywords
methyl
benzo
oxazin
oxo
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012502295A
Other languages
English (en)
Japanese (ja)
Other versions
JP5730281B2 (ja
JP2012522007A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/028878 external-priority patent/WO2010111626A2/en
Publication of JP2012522007A publication Critical patent/JP2012522007A/ja
Publication of JP2012522007A5 publication Critical patent/JP2012522007A5/ja
Application granted granted Critical
Publication of JP5730281B2 publication Critical patent/JP5730281B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012502295A 2009-03-27 2010-03-26 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤 Active JP5730281B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16413209P 2009-03-27 2009-03-27
US61/164,132 2009-03-27
PCT/US2010/028878 WO2010111626A2 (en) 2009-03-27 2010-03-26 Poly (adp-ribose) polymerase (parp) inhibitors

Publications (3)

Publication Number Publication Date
JP2012522007A JP2012522007A (ja) 2012-09-20
JP2012522007A5 true JP2012522007A5 (cg-RX-API-DMAC7.html) 2013-05-16
JP5730281B2 JP5730281B2 (ja) 2015-06-10

Family

ID=42288484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012502295A Active JP5730281B2 (ja) 2009-03-27 2010-03-26 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤

Country Status (4)

Country Link
US (1) US8669249B2 (cg-RX-API-DMAC7.html)
EP (1) EP2415767B1 (cg-RX-API-DMAC7.html)
JP (1) JP5730281B2 (cg-RX-API-DMAC7.html)
WO (1) WO2010111626A2 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106750D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
SG11201402237WA (en) 2011-12-22 2014-09-26 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EP2970282B1 (en) 2013-03-15 2019-08-21 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
EP2996692B1 (en) 2013-05-14 2021-06-30 Medizinische Hochschule Hannover Means and methods for treating cancer
AR096837A1 (es) 2013-07-08 2016-02-03 Incyte Corp Heterociclos tricíclicos como inhibidores de proteínas bet
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
MY207899A (en) 2014-04-23 2025-03-27 Incyte Holdings Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
JP6871169B2 (ja) 2015-03-02 2021-05-12 シナイ ヘルス システム 相同組換え因子
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
DK3472157T3 (da) 2016-06-20 2023-05-01 Incyte Corp Krystallinske faste former af en bet-inhibitor
CN111386269A (zh) * 2017-11-28 2020-07-07 豪夫迈·罗氏有限公司 新型杂环化合物
TW201930300A (zh) * 2017-12-15 2019-08-01 瑞士商赫孚孟拉羅股份公司 新雜環化合物
US20210052597A1 (en) 2018-01-29 2021-02-25 Cadila Healthcare Limited Heterocyclic compounds useful as antibacterial agents
CN110526907B (zh) * 2018-05-23 2021-04-23 四川大学 苯并噁嗪酮类衍生物及其应用
EP3966208A4 (en) * 2019-05-10 2024-01-03 Antidote IP Holdings, LLC COMPOUNDS AND METHODS OF TREATING CANCER
KR20220035941A (ko) * 2019-07-19 2022-03-22 아스트라제네카 아베 Parp1 억제제
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
MX2023012361A (es) * 2021-04-22 2023-10-31 Wigen Biomedicine Tech Shanghai Co Ltd Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo.
BR112023019797A2 (pt) * 2021-04-23 2023-11-07 Jiangsu Hansoh Pharmaceutical Group Co Ltd Inibidor derivado heterocíclico e método de preparação do mesmo e aplicação do mesmo
WO2023046149A1 (zh) * 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
WO2023051716A1 (zh) * 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
CN118043323A (zh) * 2021-09-30 2024-05-14 西藏海思科制药有限公司 双环衍生物parp抑制剂及其用途
CN118055933B (zh) * 2021-11-19 2025-06-06 康百达（四川）生物医药科技有限公司 选择性parp1抑制剂及其应用
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023207283A1 (en) * 2022-04-28 2023-11-02 Ningbo Newbay Technology Development Co., Ltd Compounds as parp1 inhibitiors
TW202408509A (zh) * 2022-07-14 2024-03-01 大陸商西藏海思科製藥有限公司 雜芳基衍生物的藥物組合物及其在醫藥上的應用
WO2024041605A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
CN119907799A (zh) * 2022-08-24 2025-04-29 海思科医药集团股份有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途
CN117903159A (zh) * 2022-12-30 2024-04-19 成都硕德药业有限公司 一种内酰胺类衍生物、其制备方法及用途
WO2025168048A1 (zh) * 2024-02-08 2025-08-14 上海璎黎药业有限公司 一种三键结构化合物、其药物组合物及其应用
KR20250128449A (ko) * 2024-02-20 2025-08-28 주식회사 종근당 Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
EP0313311A3 (en) 1987-10-20 1990-03-07 Ici Australia Operations Proprietary Limited Herbicidal sulfonamides
ATE336485T1 (de) * 1997-05-02 2006-09-15 Schering Ag Substituierte heterocyclen und deren verwendung in arzneimitteln
KR20010079778A (ko) 1998-09-09 2001-08-22 이시하라 겐조 제초제로 유용한 융합-벤젠 유도체
IL142128A0 (en) * 1998-09-22 2002-03-10 Kyowa Hakko Kogyo Kk [1,2,4] triazolo [1,5-c] pyrimidine derivatives
DE10056312A1 (de) 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
PE20060653A1 (es) * 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1
US8022382B2 (en) * 2005-03-11 2011-09-20 Taiwan Semiconductor Manufacturing Company, Ltd. Phase change memory devices with reduced programming current
JP2007137818A (ja) * 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd ８−ヒドロキシ−２，４（１ｈ，３ｈ）−キナゾリンジオン誘導体
MX2009009540A (es) * 2007-03-07 2009-09-16 Alantos Pharm Holding Inhibidores de metaloproteasa que contienen una porcion heterociclica.

Similar Documents

Publication Publication Date Title
JP2012522007A5 (cg-RX-API-DMAC7.html)
JP7148683B2 (ja) 血漿カリクレイン阻害剤としてのｎ－（（ヘタ）アリールメチル）－ヘテロアリール－カルボキサミド化合物
CA2793086C (en) Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
AU2005292152B2 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
JP5753194B2 (ja) 治療用化合物、及び関連する使用の方法
JP2013542937A5 (cg-RX-API-DMAC7.html)
JP6121658B2 (ja) 治療用化合物、及び関連する使用の方法
AU2012296411B2 (en) Amino quinazolines as kinase inhibitors
CA2729408C (en) Triazole derivative or salt thereof
WO2013111108A1 (en) 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO1995018097A1 (en) Anthranilic acid derivative
HU230787B1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
JP2017512794A5 (cg-RX-API-DMAC7.html)
JP2009531309A5 (cg-RX-API-DMAC7.html)
NZ763263A (en) Novel phenylpyridine derivative and pharmaceutical composition comprising the same
ES2539290T3 (es) Un derivado novedoso de benzoxazina bencimidazol, una composición farmacéutica que comprende el mismo y su uso
CA2879816C (en) Methanethione compounds having antiviral activity
CN103153990B (zh) 新型吡啶基苯并噁嗪衍生物、包含其的药物组合物及其用途
JP7616609B2 (ja) Ｒｎａウイルス感染症を処置する為のアリール－ｎ－アリール誘導体
KR101127725B1 (ko) 아미드 유도체
AU2023317959A1 (en) Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof
RU2821520C2 (ru) N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина
HK1227751A1 (en) Therapeutic compounds and related methods of use